LAE-32

LAE-32
Clinical data
Other namesLAE; Lysergic acid ethylamide; d-Lysergic acid ethylamide; d-Ethyllysergamide,
Routes of
administration		Oral
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal
Identifiers
IUPAC name
  • (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21N3O
Molar mass295.386 g·mol−1
3D model (JSmol)
SMILES
  • CCNC(=O)[C@@H]2C=C1c3cccc4[nH]cc(C[C@H]1N(C)C2)c34
InChI
  • InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1 checkY
  • Key:VEBWTGYUIBTVNR-MLGOLLRUSA-N checkY
  (verify)

D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine. It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.

It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.

References



    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.